Pu-Yuan Xing (Puyuan Xing)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Topics

Epidermal Growth Factor Receptor

Circulating Tumor

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Journal of translational medicine

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Lige Wu, Zihua Zou, Yan Li, Xuezhi Hao, Jianming Ying, Junling Li, Pu-Yuan Xing
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs. Journal of translational medicine 22 (1) (2024)
Lige Wu, Zihua Zou, Yan Li, Xuezhi Hao, Jianming Ying, Junling Li, Pu-Yuan Xing
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs. Journal of translational medicine 22 (1) (2024)
Lige Wu, Zihua Zou, Yan Li, Xuezhi Hao, Jianming Ying, Junling Li, Pu-Yuan Xing
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs. Journal of translational medicine 22 (1) (2024)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wang
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thoracic cancer (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Fei Xu, Jun-Ling Li, Pu-Yuan Xing, Yutao Liu, Yan Wang
Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse. Cancer medicine (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics (2023)
Fei Xu, Heng-Chi Chen, Hai-Yan Xu, Jun-Ling Li, Xuezhi Hao, Pu-Yuan Xing, Jianming Ying, Yan Wang
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 13 (22) (2022)
Yan Li, Ziyi Xu, Shou-Zheng Wang, Yi-Xiang Zhu, Di Ma, Yuxin Mu, Jian-Ming Ying, Jun-Ling Li, Pu-Yuan Xing
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic cancer 13 (15) (2022)
Tongji Xie, Zhenghao Liu, Yan Li, Shou-Zheng Wang, Yixin Zhai, Fei Teng, Xuezhi Hao, Yan Wang, Hongyu Wang, Xin Zhang, Xi Wu, Jianming Ying, Jun-Ling Li, Ye Zhang, Yuefei Deng, Pu-Yuan Xing
Evolutionary characteristics and immunological divergence of lung and brain metastasis lesions in NSCLC. Molecular cancer research : MCR (2022)
Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Jun-Ling Li, Pu-Yuan Xing
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thoracic cancer 12 (19) (2021)
Tongji Xie, Zihua Zou, Chengcheng Liu, Yi-Xiang Zhu, Ziyi Xu, Le Wang, Jun-Ling Li, Pu-Yuan Xing
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM 2021 (2021)
Hao-Hua Zhu, Yu-Tao Liu, Yu Feng, Li-Na Zhang, Tong-Mei Zhang, Gui-Lan Dong, Pu-Yuan Xing, Hong-Yu Wang, Yuan-Kai Shi, Xing-Sheng Hu
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis. Thoracic cancer 12 (20) (2021)
Zihua Zou, Xuezhi Hao, Cuiying Zhang, Haojing Li, Guilan Dong, Yumei Peng, Kewei Ma, Ye Guo, Li Shan, Yan Zhang, Li Liang, Yangchun Gu, Pu-Yuan Xing, Jun-Ling Li
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. Thoracic cancer (2021)
Jinyao Zhang, Yan Wang, Ziling Liu, Lin Wang, Yu Yao, Yutao Liu, Xue Zhi Hao, Jianyang Wang, Pu-Yuan Xing, Jun-Ling Li
Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thoracic cancer (2021)
Chunfang Hu, Jiyan Dong, Li Liu, Jingbo Liu, Xujie Sun, Fei Teng, Xin Wang, Jianming Ying, Junling Li, Pu-Yuan Xing, Lin Yang
ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China. Thoracic cancer 13 (3) (2021)
Yuxin Mu, Xuezhi Hao, Ke Yang, Di Ma, Shouzheng Wang, Ziyi Xu, Junling Li, Pu-Yuan Xing
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Targeted oncology 14 (3) (2020)